GOLDENWELL BIOTECH, INC. (GWLL) stock: key figures, P/E, revenue and dividend
Consumer Staples · United States · ISIN US38138N1046
GOLDENWELL BIOTECH, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 55.00 USD |
| Gross profit | 12.00 USD |
| Operating income | -113,326.00 USD |
| EBIT | -288,071.00 USD |
| Net income | -296,471.00 USD |
| Diluted EPS – continuing operations | 0.00 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About GOLDENWELL BIOTECH, INC.
Goldenwell Biotech, Inc. engages in the nutraceutical and dietary supplements business. It offers JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Solon, Ohio.
More stocks
- Salazar Resources Limited (SRL.V)
- Camus Engineering & Construction Inc (013700.KS)
- Gamma Nu Inc (192410.KQ)
- KTIS Corporation (058860.KS)
- Wentel Engineering Holdings Berhad (0298.KL)
- Sam-A Pharm. Co. Ltd (009300.KQ)
- Kaulin Mfg (1531.TW)
- Nickel 28 Capital Corp (NKL.V)
- Autocount Dotcom Berhad (0276.KL)
- LeRain Technology Co., Ltd. (6921.TW)
- PodcastOne, Inc. (PODC)
- Lingotes (LGT.MC)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.